The biosimilars market is not all about the United States,
Europe, and Japan. Although these developed markets account for 80% of branded
biologics sales, the remaining 20% is from rapidly growing rapidly markets that
are most in need of more affordable healthcare. Regulators in more than 20 of
the growth markets have adopted biosimilars guidelines and are eager to
establish their own biosimilars industries. This situation has led to a wide
range of companies embarking on biosimilars development within their domestic
markets and overseas. Understanding who the key competitors are in each region
is critical to biosimilar and branded biologics companies.
Markets covered: Global R&D pipeline of biosimilars and in-depth analysis of biosimilars competitive landscape in Europe, United States, India, South Korea, and Brazil.
Primary research: Surveys with 549 specialist physicians across six different specialties in the United States and Europe. Surveys with an additional 60 U.S. managed care organization directors and 10 telephone interviews with key European payer advisors. Primary market research with key stakeholders to assess the following:
- Current opinions on biosimilars developed in emerging markets.
- How country of origin will affect biosimilar uptake.
- Perceptions of regulatory guidance.
Global Biosimilars Development Pipeline Deliverable: Includes more than 200 biosimilars development candidates targeting 32 different reference brands across 13 drug classes.